Shenzhen New Industries Biomedical
Shenzhen New Industries Biomedical Engineering Co., Ltd., engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in China and internationally. It offers immunoassay machine, biochemistry/electrolyte, integrated system, lab automation, molecular diagnostics, hemolumi and rapid test solutions. The company was found… Read more
Shenzhen New Industries Biomedical (300832) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.069x
Based on the latest financial reports, Shenzhen New Industries Biomedical (300832) has a cash flow conversion efficiency ratio of 0.069x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥606.21 Million) by net assets (CN¥8.74 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shenzhen New Industries Biomedical - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Shenzhen New Industries Biomedical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Shenzhen New Industries Biomedical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenzhen New Industries Biomedical ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ACM Research Shanghai Inc
SHG:688082
|
0.006x |
|
TOHO GAS CO. LTD
F:59W
|
N/A |
|
Trinity Industries Inc
NYSE:TRN
|
0.035x |
|
Anker Innovations Technology Co Ltd
SHE:300866
|
0.044x |
|
Maxis Bhd
KLSE:6012
|
0.107x |
|
Rising Nonferrous Metals Share Co Ltd
SHG:600259
|
0.103x |
|
Shenzhen Intellifusion Technologies Co. Ltd. A
SHG:688343
|
N/A |
|
Maruwa Co.,Ltd.
PINK:MAWAF
|
N/A |
Annual Cash Flow Conversion Efficiency for Shenzhen New Industries Biomedical (2012–2024)
The table below shows the annual cash flow conversion efficiency of Shenzhen New Industries Biomedical from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥8.58 Billion | CN¥1.36 Billion | 0.158x | -15.87% |
| 2023-12-31 | CN¥7.54 Billion | CN¥1.42 Billion | 0.188x | +25.01% |
| 2022-12-31 | CN¥6.40 Billion | CN¥962.39 Million | 0.150x | +9.15% |
| 2021-12-31 | CN¥5.61 Billion | CN¥773.22 Million | 0.138x | -32.23% |
| 2020-12-31 | CN¥4.80 Billion | CN¥976.65 Million | 0.203x | -23.28% |
| 2019-12-31 | CN¥3.14 Billion | CN¥831.73 Million | 0.265x | -10.68% |
| 2018-12-31 | CN¥2.37 Billion | CN¥701.97 Million | 0.297x | +0.19% |
| 2017-12-31 | CN¥1.77 Billion | CN¥524.73 Million | 0.296x | -13.68% |
| 2016-12-31 | CN¥1.42 Billion | CN¥486.81 Million | 0.343x | +14.71% |
| 2015-12-31 | CN¥1.02 Billion | CN¥305.93 Million | 0.299x | -27.98% |
| 2014-12-31 | CN¥610.52 Million | CN¥253.47 Million | 0.415x | +13.70% |
| 2013-12-31 | CN¥378.84 Million | CN¥138.33 Million | 0.365x | +62.39% |
| 2012-12-31 | CN¥248.18 Million | CN¥55.80 Million | 0.225x | -- |